Overview
Status
Active
Registry date
2020-03-12
Share capital
5,000.00 PLN
Registered address
ul. Mełgiewska 7-9, 20-952 Lublin, Poland
Financials
Revenue history (in k)
Filing timeliness
1 of 6 financial statements was filed late (for 2021, 37 days late). 5 of 6 audited by a statutory auditor.
- 202512/07/2026
- 202430/06/2025
- 202325/06/2024
- 202211/07/2023
- 202121/08/2022
- 202025/06/2021
Filed on timeDelayFiling deadline
Data and insights are generated automatically from financial statements – they may contain errors and are neither a credit assessment nor business advice.
Statistics
How the company ranks by revenue within its industry, region and across Poland in 2025.
Results vs industry
Revenue
This companyUSD 2.58kMedianUSD 917.74kAverageUSD 25.73m
Net profit
This companyUSD -8.35kMedianUSD 14.44kAverageUSD 2.75m
Operating costs
This companyUSD 10.71kMedianUSD 860.03kAverageUSD 21.34m
Assets
This companyUSD 9.09kMedianUSD 883.09kAverageUSD 31.39m
Industry
Authorized Representatives
Jan Donart – President of the Management Board
Jan Pankowski – Management Board Member
Manner of representation
Each member of the management board is authorized to make declarations on behalf of the company independently.
Ownership
| Owner | Shares | Share value | Stake |
|---|---|---|---|
Jan Donartage 39 | 60 | $810.37 | 60% |
Jan Pankowskiage 51 | 40 | $540.25 | 40% |
Beneficial owners
| Person | Rights |
|---|---|
Bank accounts
Registered as a VAT taxpayer on 2020-07-22.
72 1090 2590 0000 0001 4465 3443
Debt
No entries in the National Debtors Register (KRZ).
Public aid
| Grant date | Purpose | Gross amount | Granting body | |
|---|---|---|---|---|
| Mar 20, 2020 | De minimis aid (in accordance with Commission Regulation No 1407/2013 or earlier) | $14,036$14,036 | Park Naukowo-Technologiczny Spólka z Ograniczoną Odpowiedzialnością sp. z o.o. |
Competitors
| Name | Revenue | Website | ||
|---|---|---|---|---|
| Przedsiębiorstwo Farmaceutyczne Leki Natury Tadeusz Polańskisp. z o.o. | $893,738.50 | lekinatury.pl | ||
| LideoS.A. | $95,067.91 | lideo.tech | ||
| Munar PharmaS.A. | $85,649.72 | munar.pl | ||
| BIO Animalisp. z o.o. | $49,176.96 | proanimali.com | ||
| Ampliconsp. z o.o. | $48,330.99 | amplicon.pl | ||
| Xenira Pharmaceuticalssp. z o.o. | $26,670.82 | xenirapharma.com | ||
| Sanford Biotechsp. z o.o. | $2,586.64 | sanfordbiotech.com | ||
| Cefeasp. z o.o. | $294.66 | cefea.pl | ||
| Auxilius PharmaS.A. | $0.83 | auxiliuspharma.com | ||
| Powerpharmasp. z o.o. | – | powerpharma.eu |
FAQ
The main business activity of Medorion focuses on manufacture of pharmaceutical preparations.
The company was registered in the Polish National Court Register (KRS) on March 12, 2020.
The headquarters is located at: ul. Mełgiewska 7-9, 20-952 Lublin.
The share capital of the company is PLN 5,000 (approx. $1,351).
The latest available financial statement covers the period from January 1, 2024 to December 31, 2024.
The company reported a revenue of $1,684 in 2024, which is a decrease of 78.9% compared to 2023.
No, the company recorded a net loss of $4,155 in 2024. For comparison, in 2023 the loss was $1,238, meaning the company increased its loss by 218.6%.
The largest operating cost category falls under external services. This category amounted to $4,280 in 2024, representing 76% of all operating expenses.
Last updated: 2026-07-16